Cargando…

Editorial: Cancer-Associated Defects in the DNA Damage Response: Drivers for Malignant Transformation and Potential Therapeutic Targets

Detalles Bibliográficos
Autores principales:	van Vugt, Marcel A. T. M., Reinhardt, H. Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686599/ https://www.ncbi.nlm.nih.gov/pubmed/26734064 http://dx.doi.org/10.3389/fgene.2015.00355

Ejemplares similares

Editorial: Exploiting DNA Damage Response in the Era of Precision Oncology
por: Zimmer, Yitzhak, et al.
Publicado: (2020)

Editorial: Harnessing DNA Damage Response in Gynecologic Malignancies
por: Tse, Ka Yu, et al.
Publicado: (2022)

DNA Damage Tolerance Pathways in Human Cells: A Potential Therapeutic Target
por: Ler, Ashlynn Ai Li, et al.
Publicado: (2022)

Editorial: Transcription Factors Drivers of Malignancy, Progression and Poor Outcomes in Breast Cancer
por: Parisi, Eva, et al.
Publicado: (2022)

Editorial: Targeting DNA damage response to enhance antitumor innate immunity in radiotherapy
por: Valvo, Victoria, et al.
Publicado: (2023)

Targeting DNA damage response as a potential therapeutic strategy for head and neck squamous cell carcinoma
por: Lei, Huimin, et al.
Publicado: (2022)

Editorial: Targeting DNA repair and the DNA damage response: Beyond the standard PI3 kinase-like kinases
por: Turchi, John J., et al.
Publicado: (2022)

Editorial: Grappling with the Multifaceted World of the DNA Damage Response
por: Porro, Antonio
Publicado: (2016)

Editorial: Altered Expression of Proteins in Cancer: Function and Potential Therapeutic Targets
por: Pessoa, João, et al.
Publicado: (2022)

The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer
por: Burgess, Joshua T., et al.
Publicado: (2020)

Editorial: Advances of Targeted Therapy in Gynecologic Malignancies
por: Qiu, Haifeng, et al.
Publicado: (2022)

Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets
por: Marsh, Deborah J., et al.
Publicado: (2014)

Editorial: Metabolism As a Therapeutic Target
por: Columbano, Amedeo, et al.
Publicado: (2017)

Editorial: Novel targeted drugs for indolent lymphoid malignancies
por: Robak, Tadeusz, et al.
Publicado: (2023)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

Transcription Factors as Novel Therapeutic Targets and Drivers of Prostate Cancer Progression
por: Xie, Kangzhe, et al.
Publicado: (2022)

Editorial: Translational research in the diagnosis and development of therapeutics for peritoneal surface malignancies
por: Chia, Claramae Shulyn, et al.
Publicado: (2023)

Editorial: Altered expression of proteins in cancer: function and potential therapeutic targets, volume II
por: Pessoa, João, et al.
Publicado: (2023)

Editorial: Immunometabolism and therapeutic targeting of aggressive cancers
por: Ždralević, Maša, et al.
Publicado: (2023)

Germline and somatic drivers in inherited hematologic malignancies
por: Zoller, Julian, et al.
Publicado: (2023)

Posttranscriptional regulation of gene expression—adding another layer of complexity to the DNA damage response
por: Boucas, Jorge, et al.
Publicado: (2012)

Editorial: The advances in proteomics and targeted therapy of malignant brain tumours
por: Chen, Anjing, et al.
Publicado: (2023)

NLRR1 Is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers
por: Takatori, Atsushi, et al.
Publicado: (2021)

Lysine specific demethylase 1 is a molecular driver and therapeutic target in sarcoma
por: Dreher, Rachel D., et al.
Publicado: (2023)

DNA Damage Inducible Transcript 4 Gene: The Switch of the Metabolism as Potential Target in Cancer
por: Tirado-Hurtado, Indira, et al.
Publicado: (2018)

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications
por: Sun, Wei, et al.
Publicado: (2021)

Editorial: Systemic immune dysregulation in malignant disease: Insights, monitoring and therapeutic exploitation
por: Christopoulos, Petros, et al.
Publicado: (2023)

Editorial: Endocrine malignancies: from pathophysiology to current clinical and surgical therapeutic approaches
por: Tarallo, M., et al.
Publicado: (2023)

Revisiting Glycogen in Cancer: A Conspicuous and Targetable Enabler of Malignant Transformation
por: Khan, Tashbib, et al.
Publicado: (2020)

Neuropilin-1 as Therapeutic Target for Malignant Melanoma
por: Graziani, Grazia, et al.
Publicado: (2015)

Editorial: Tumor Cell Metabolism and Autophagy as Therapeutic Targets
por: Jacobo-Herrera, Nadia, et al.
Publicado: (2020)

Editorial: Molecular Targets and Therapeutic Strategies in Gynecological Cancers
por: Lu, Ziwen, et al.
Publicado: (2022)

Editorial: Innovations in surgical oncology
por: Aramini, Beatrice, et al.
Publicado: (2023)

Common Molecular Alterations in Canine Oligodendroglioma and Human Malignant Gliomas and Potential Novel Therapeutic Targets
por: Mitchell, Dana, et al.
Publicado: (2019)

Driver Gene Alterations in Malignant Progression of Gastric Cancer
por: Dong, Yuanqiang, et al.
Publicado: (2022)

Clinical and Histological Prognostic Factors of Recurrence and Malignant Transformation in a Large Series of Oral Potentially Malignant Disorders
por: Lorini, Luigi, et al.
Publicado: (2022)

Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival
por: Herrero, Ana Belén, et al.
Publicado: (2017)

A Lack of Effectiveness in the ATM-Orchestrated DNA Damage Response Contributes to the DNA Repair Defect of HPV-Positive Head and Neck Cancer Cells
por: Köcher, Sabrina, et al.
Publicado: (2022)

Editorial: The Microenvironment in Pancreatic Cancer and Therapeutic Strategies Targeting Microenvironment
por: Duan, Wanxing, et al.
Publicado: (2022)

Editorial: Biomarkers, functional mechanisms, and therapeutic potentials in gastrointestinal cancers
por: Huang, Jun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_krofi1gicov1qru3t8edcv1tvp